Kisqali gets early breast cancer approval in Europe
Novartis' fast-growing breast cancer drug gets another growth driver as EU approves adjuvant use in patients with early-stage HR+, HER2- tumours
Newsletters and Deep Dive digital magazine
Novartis' fast-growing breast cancer drug gets another growth driver as EU approves adjuvant use in patients with early-stage HR+, HER2- tumours
In a new pharmaphorum podcast, editor-in-chief Jonah Comstock speaks with Phil Johnson, MD, president and CEO of Interius Biotherapeutics.
Medigene slashes staff and delays trials of its lead TCR therapy candidate as it refocuses its pipeline
Roche has upgraded its partnership with off-the-shelf CAR-T therapy specialist Poseida to a $1 billion-plus takeover bid
After a disappointing result with Truqap in triple-negative breast cancer, AstraZeneca chalks up a win in prostate cancer
Editor's Picks
Newsletters and Deep Dive
digital magazine